[1]
|
Chalan, P., Di Dalmazi, G., Pani, F., et al. (2018) Thyroid Dysfunctions Secondary to Cancer Immunotherapy. Journal of Endocrinological Investigation, 41, 625-638. https://doi.org/10.1007/s40618-017-0778-8
|
[2]
|
Cuenca, D., Rodríguez-Meléndez, E., Aguilar-Soto, M., et al. (2021) Incidence and Clinical Characteristics of Thyroid Abnormalities in Cancer Patients Treated with Immune Checkpoint Inhibitors. Gaceta Médica De México, 157, 305-310. https://doi.org/10.24875/GMM.M21000560
|
[3]
|
Darnell, E.P., Mooradian, M.J., Baruch, E.N., et al. (2020) Immune-Related Adverse Events (IrAEs): Diagnosis, Management, and Clinical Pearls. Current Oncology Reports, 22, Article No. 39. https://doi.org/10.1007/s11912-020-0897-9
|
[4]
|
Haanen, J., Obeid, M., Spain, L., et al. (2022) Management of Toxicities from Immunotherapy: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 33, 1217-1238. https://doi.org/10.1016/j.annonc.2022.10.001
|
[5]
|
Barroso-Sousa, R., Barry, W.T., Garrido-Castro, A.C., et al. (2018) Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-Analysis. JAMA Oncology, 4, 173-182. https://doi.org/10.1001/jamaoncol.2017.3064
|
[6]
|
Arnaud-Coffin, P., Maillet, D., Gan, H.K., et al. (2019) A Systematic Review of Adverse Events in Randomized Trials Assessing Immune Checkpoint Inhibitors. International Journal of Cancer, 145, 639-648. https://doi.org/10.1002/ijc.32132
|
[7]
|
Byun, D.J., Wolchok, J.D., Rosenberg, L.M., et al. (2017) Cancer Immunotherapy—Immune Checkpoint Blockade and Associated Endocrinopathies. Nature Reviews Endocrinology, 13, 195-207. https://doi.org/10.1038/nrendo.2016.205
|
[8]
|
Ferrari, S.M., Fallahi, P., Galetta, F., et al. (2018) Thyroid Disorders Induced by Checkpoint Inhibitors. Reviews in Endocrine and Metabolic Disorders, 19, 325-333. https://doi.org/10.1007/s11154-018-9463-2
|
[9]
|
Sznol, M., Postow, M.A., Davies, M.J., et al. (2017) Endocrine-Related Adverse Events Associated with Immune Checkpoint Blockade and Expert Insights on Their Management. Cancer Treatment Reviews, 58, 70-76. https://doi.org/10.1016/j.ctrv.2017.06.002
|
[10]
|
Muir, C.A., Menzies, A.M., Clifton-Bligh, R., et al. (2020) Thyroid Toxicity Following Immune Checkpoint Inhibitor Treatment in Advanced Cancer. Thyroid, 30, 1458-1469. https://doi.org/10.1089/thy.2020.0032
|
[11]
|
罗景梅, 杨中策, 潘俐, 张丽华. 免疫检查点抑制剂所致内分泌不良反应处理流程研究进展[J]. 解放军医学杂志, 2021(2): 200-206.
|
[12]
|
Rubino, R., Marini, A., Roviello, G., et al. (2021) Endocrine-Related Adverse Events in a Large Series of Cancer Patients Treated with Anti-PD1 Therapy. Endocrine, 74, 172-179. https://doi.org/10.1007/s12020-021-02750-w
|
[13]
|
Li, X., Wang, X., Wang, S., et al. (2023) Thyroid Dysfunction Induced by Immune Checkpoint Inhibitors and Tumor Progression during Neoadjuvant Therapy of Non-Small Cell Lung Cancer: A Case Report and Literature Review. Oncology Letters, 26, Article No. 496. https://doi.org/10.3892/ol.2023.14083
|
[14]
|
Wang, Y., Wang, C., Qiu, J., et al. (2022) Targeting CD96 Overcomes PD-1 Blockade Resistance by Enhancing CD8 TIL Function in Cervical Cancer. Journal for Immunotherapy of Cancer, 10, e003667. https://doi.org/10.1136/jitc-2021-003667
|
[15]
|
Meng, X., Liu, X., Guo, X., et al. (2018) FBXO38 Mediates PD-1 Ubiquitination and Regulates Anti-Tumour Immunity of T Cells. Nature, 564, 130-135. https://doi.org/10.1038/s41586-018-0756-0
|
[16]
|
Bhardwaj, M., Chiu, M.N. and Pilkhwal Sah, S. (2022) Adverse Cutaneous Toxicities by PD-1/PD-L1 Immune Checkpoint Inhibitors: Pathogenesis, Treatment, and Surveillance. Cutaneous and Ocular Toxicology, 41, 73-90. https://doi.org/10.1080/15569527.2022.2034842
|
[17]
|
Tang, Q., Chen, Y., Li, X., et al. (2022) The Role of PD-1/PD-L1 and Application of Immune-Checkpoint Inhibitors in Human Cancers. Frontiers in Immunology, 13, Article ID: 964442. https://doi.org/10.3389/fimmu.2022.964442
|
[18]
|
Suijkerbuijk, K.P.M., Kapiteijn, E. and Verheijden, R.J. (2020) Management of Immune-Related Adverse Events Affecting Outcome in Patients Treated with Checkpoint Inhibitors. JAMA Oncology, 6, 1300-1301. https://doi.org/10.1001/jamaoncol.2020.1932
|
[19]
|
Kobayashi, T., Iwama, S., Yasuda, Y., et al. (2018) Patients with Antithyroid Antibodies Are Prone to Develop Destructive Thyroiditis by Nivolumab: A Prospective Study. Journal of the Endocrine Society, 2, 241-251. https://doi.org/10.1210/js.2017-00432
|
[20]
|
Osorio, J.C., Ni, A., Chaft, J.E., et al. (2017) Antibody-Mediated Thyroid Dysfunction during T-Cell Checkpoint Blockade in Patients with Non-Small-Cell Lung Cancer. Annals of Oncology, 28, 583-589. https://doi.org/10.1093/annonc/mdw640
|
[21]
|
Fentiman, I.S., Balkwill, F.R., Thomas, B.S., et al. (1988) An Autoimmune Aetiology for Hypothyroidism Following Interferon Therapy for Breast Cancer. European Journal of Cancer and Clinical Oncology, 24, 1299-1303. https://doi.org/10.1016/0277-5379(88)90219-2
|
[22]
|
Lowndes, S.A., Asher, R. and Middleton, M.R. (2010) Thyrotoxicosis with Pegylated Interferon Alfa-2b. Archives of Dermatology, 146, 1273-1275. https://doi.org/10.1001/archdermatol.2010.306
|
[23]
|
Scalzo, S., Gengaro, A., Boccoli, G., et al. (1990) Primary Hypothyroidism Associated with Interleukin-2 and Interferon Alpha-2 Therapy of Melanoma and Renal Carcinoma. European Journal of Cancer and Clinical Oncology, 26, 1152-1156. https://doi.org/10.1016/0277-5379(90)90275-X
|
[24]
|
Atkins, M.B., Mier, J.W., Parkinson, D.R., et al. (1988) Hypothyroidism after Treatment with Interleukin-2 and Lymphokine-Activated Killer Cells. New England Journal of Medicine, 318, 1557-1563. https://doi.org/10.1056/NEJM198806163182401
|
[25]
|
Abdel-Rahman, O., ElHalawani, H. and Fouad, M. (2016) Risk of Endocrine Complications in Cancer Patients Treated with Immune Check Point Inhibitors: A Meta-Analysis. Future Oncology, 12, 413-425. https://doi.org/10.2217/fon.15.222
|
[26]
|
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., et al. (2015) Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. New England Journal of Medicine, 373, 23-34. https://doi.org/10.1056/NEJMoa1504030
|
[27]
|
Hellmann, M.D., Rizvi, N.A., Goldman, J.W., et al. (2017) Nivolumab plus Ipilimumab as First-Line Treatment for Advanced Non-Small-Cell Lung Cancer (CheckMate 012): Results of an Open-Label, Phase 1, Multicohort Study. The Lancet Oncology, 18, 31-41. https://doi.org/10.1016/S1470-2045(16)30624-6
|
[28]
|
Morris, G.P., Brown, N.K. and Yi-Chi, M.K. (2009) Naturally-Existing CD4 CD25 Foxp3 Regulatory T Cells Are Required for Tolerance to Experimental Autoimmune Thyroiditis Induced by Either Exogenous or Endogenous Autoantigen. Journal of Autoimmunity, 33, 68-76. https://doi.org/10.1016/j.jaut.2009.03.010
|
[29]
|
Francisco, L.M., Sage, P.T. and Sharpe, A.H. (2010) The PD-1 Pathway in Tolerance and Autoimmunity. Immunological Reviews, 236, 219-242. https://doi.org/10.1111/j.1600-065X.2010.00923.x
|
[30]
|
Yamauchi, I., Sakane, Y., Fukuda, Y., et al. (2017) Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study. Thyroid, 27, 894-901. https://doi.org/10.1089/thy.2016.0562
|
[31]
|
Delivanis, D.A., Gustafson, M.P., Bornschlegl, S., et al. (2017) Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights into Underlying Involved Mechanisms. The Journal of Clinical Endocrinology & Metabolism, 102, 2770-2780. https://doi.org/10.1210/jc.2017-00448
|